Get the Stockscreener App
10.01
2.44%
-0.25
After Hours:
10.01
Neogenomics Inc stock is traded at $10.01, with a volume of 1.50M.
It is down -2.44% in the last 24 hours and down -21.74% over the past month.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
See More
Previous Close:
$10.26
Open:
$10.19
24h Volume:
1.50M
Relative Volume:
0.81
Market Cap:
$1.30B
Revenue:
$628.25M
Net Income/Loss:
$-78.55M
P/E Ratio:
-16.15
EPS:
-0.62
Net Cash Flow:
$-29.73M
1W Performance:
-10.38%
1M Performance:
-21.74%
6M Performance:
+58.64%
1Y Performance:
-21.31%
1-Day Range:
$10.00
$10.38
1-Week Range:
$9.28
$11.61
52-Week Range:
$4.72
$13.74
Neogenomics Inc Stock (NEO) Company Profile
Name
Neogenomics Inc
Sector
Industry
Phone
(239) 768-0600
Address
9490 NEOGENOMICS WAY, FORT MYERS, FL
Compare NEO vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
10.01 | 1.33B | 628.25M | -78.55M | -29.73M | -0.62 |
|
TMO
Thermo Fisher Scientific Inc
|
515.12 | 192.95B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
211.25 | 147.43B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
630.73 | 50.70B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
126.34 | 35.90B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
328.66 | 32.13B | 3.17B | 642.63M | 539.81M | 10.77 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-29-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-15-25 | Initiated | Guggenheim | Neutral |
| Apr-30-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jan-13-25 | Downgrade | The Benchmark Company | Buy → Hold |
| Dec-10-24 | Initiated | Jefferies | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Aug-21-23 | Upgrade | Stephens | Equal-Weight → Overweight |
| May-16-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-09-23 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-24-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-01-23 | Upgrade | Needham | Hold → Buy |
| Aug-26-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-22-22 | Downgrade | Needham | Buy → Hold |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Mar-29-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-29-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jan-18-22 | Resumed | Stephens | Overweight |
| Dec-16-21 | Initiated | Cowen | Outperform |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-14-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-03-21 | Initiated | Goldman | Buy |
| Feb-25-21 | Resumed | Needham | Buy |
| Feb-25-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-28-21 | Initiated | Truist | Buy |
| Dec-11-20 | Resumed | BTIG Research | Buy |
| Oct-28-20 | Reiterated | Needham | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Aug-28-20 | Initiated | Guggenheim | Buy |
| Jul-29-20 | Reiterated | Needham | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Buy |
| Apr-21-20 | Resumed | Stephens | Overweight |
| Mar-02-20 | Resumed | Craig Hallum | Buy |
| Feb-28-20 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Jan-23-20 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Oct-30-19 | Reiterated | Needham | Buy |
| May-01-19 | Reiterated | Needham | Buy |
| Mar-29-19 | Reiterated | Needham | Buy |
| Jan-03-19 | Initiated | Needham | Buy |
| Oct-24-18 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Aug-21-18 | Initiated | Leerink Partners | Outperform |
| May-02-18 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-11-17 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-24-17 | Initiated | Gabelli & Co | Buy |
| Dec-15-16 | Initiated | Cantor Fitzgerald | Overweight |
View All
Neogenomics Inc Stock (NEO) Latest News
UBS Maintains Hold on NeoGenomics, Inc. (NEO) on Feb 18, 2026 - Meyka
NeoGenomics Faces High-Stakes Risk as Test Reliability and Diagnostic Errors Threaten Reputation and Legal Exposure - TipRanks
EV Market: Can NeoGenomics Inc deliver alpha2025 Year in Review & Smart Investment Allocation Insights - baoquankhu1.vn
NeoGenomics (NASDAQ:NEO) Trading Down 8.9%Should You Sell? - MarketBeat
NeoGenomics (NEO) Stock Drops After 2026 Outlook Misses ExpectationsNews and Statistics - IndexBox
Weekly Trades: Will ChoiceOne Financial Services Inc benefit from green energy policies2025 Performance Recap & Fast Moving Market Watchlists - baoquankhu1.vn
Why NeoGenomics (NEO) Shares Are Falling Today - Finviz
NeoGenomics, Inc. (NASDAQ:NEO) Q4 2025 Earnings Call Transcript - Insider Monkey
NeoGenomics to Participate in Upcoming Investor Conferences - The Joplin Globe
NEO Q4 Deep Dive: Product Mix Shift and Guidance Weigh on Outlook - Finviz
NeoGenomics Q4 2025 slides: 11% revenue growth, RaDaR ST launch imminent By Investing.com - Investing.com South Africa
Labcorp (LH) Q4 2025 Earnings Call Transcript - AOL.com
NeoGenomics PanTracer Pro Launch Adds New Dimension To Growth Story - Yahoo Finance
NeoGenomics Earnings Call Signals Growth With Caveats - TipRanks
Needham raises Neogenomics stock price target on 2027 estimates - Investing.com Australia
Needham raises Neogenomics stock price target on 2027 estimates By Investing.com - Investing.com South Africa
NeoGenomics (NASDAQ:NEO) Shares Gap DownTime to Sell? - MarketBeat
NeoGenomics Q4 2025 Earnings Call Transcript - MarketBeat
NeoGenomics Q4 2025 slides: 11% revenue growth, RaDaR ST launch imminent - Investing.com
NeoGenomics Reports Fourth Quarter and Full Year 2025 Results - BioSpace
NeoGenomics Q4 Earnings Call Highlights - MarketBeat
NeoGenomics, Inc. (NEO) Investor Outlook: Assessing The 27.97% Potential Upside - DirectorsTalk Interviews
Earnings call transcript: NeoGenomics Q4 2025 earnings beat expectations - Investing.com
NeoGenomics (NEO) Q4 2025 Earnings Call Transcript - The Globe and Mail
NeoGenomics: Q4 Earnings Snapshot - KVUE
NeoGenomics (NEO) Q4 Earnings and Revenues Surpass Estimates - Yahoo Finance
NeoGenomics Q4 2025 Earnings Report & 2026 Guidance | Financial ResultsNews and Statistics - IndexBox
NeoGenomics shares fall over 5% despite earnings beat By Investing.com - Investing.com South Africa
NeoGenomics shares fall over 5% despite earnings beat - Investing.com UK
Neogenomics reports fourth quarter and full year 2025 results - marketscreener.com
NeoGenomics’s (NASDAQ:NEO) Q4 CY2025 Sales Beat Estimates - Yahoo Finance
NeoGenomics (NASDAQ:NEO) Announces Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
NEOGENOMICS ($NEO) Releases Q4 2025 Earnings - Quiver Quantitative
(NEO) NeoGenomics Expects Full Year 2026 Revenue Range $793M$801M, vs. FactSet Est of $796.6M - marketscreener.com
Earnings Flash (NEO) NeoGenomics, Inc. Reports Q4 Revenue $190.2M, vs. FactSet Est of $188.5M - marketscreener.com
Press Release: NeoGenomics Reports Fourth Quarter and Full Year 2025 Results - 富途牛牛
How NeoGenomics (NASDAQ:NEO) Performs Amid Fluctuations In Nasdaq Today - Kalkine Media
NeoGenomics, Inc. (NASDAQ:NEO) Sees Significant Growth in Short Interest - MarketBeat
NeoGenomics: Fourth Quarter Earnings Overview - Bitget
Exploring NeoGenomics's Earnings Expectations - Benzinga
NeoGenomics earnings in the spotlight as analysts eye profitability - Investing.com UK
NeoGenomics earnings in the spotlight as analysts eye profitability By Investing.com - Investing.com Canada
NeoGenomics Announces Launch of New Cancer Assay PanTracer Pro - Finviz
NeoGenomics (NEO) Q4 Earnings Report Preview: What To Look For - Finviz
Will PanTracer Pro’s Integrated Tumor Profiling Platform Change NeoGenomics’ (NEO) Precision Oncology Narrative? - Yahoo Finance
NeoGenomics PanTracer Pro Launch Sets New Test Against Weak Share Performance - Sahm
How (NEO) Movements Inform Risk Allocation Models - Stock Traders Daily
Can NeoGenomics Inc. stock outperform in a bear marketBear Alert & Short-Term Swing Trade Alerts - mfd.ru
Can NeoGenomics Inc. deliver alphaWeekly Stock Report & Weekly Consistent Profit Watchlists - mfd.ru
Will NeoGenomics Inc. stock benefit from sector rotationJuly 2025 Momentum & Free Technical Pattern Based Buy Signals - mfd.ru
Will NeoGenomics Inc. stock reach Wall Street targetsJuly 2025 Update & Verified Entry Point Signals - mfd.ru
Neogenomics Inc Stock (NEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.95%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):